Novel drying method for advanced materials

先进材料的新型干燥方法

• 批准号: 102931
• 金额: $ 5.73万
• 依托单位: WILLINGSFORD LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102931
• 关键词: Novel; drying; method; advanced; materials

Acapsil is a CE-marked novel first-in-class advanced biomaterial, which has demonstrated effects in wound care. Annually in the UK, 2.2 mill wounds require treatment causing direct costs to the NHS of £5.3 bn. Acapsil accelerates wound healing by 60% and reduces bed-days by 31% for hospital in-patients with acute and chronic wounds and ulcers. Estimates indicate that Acapsil can reduce the costs of wound care by 25-30%. Acapsil is patented in all major markets world-wide. The properties of Acapsil are to a high degree determined by the manufacturing process and currently a single step in the process is preventing large-scale manufacturing. Considerable research has been dedicated to solving this problem and a solution has been found which has been tested and demonstrated to work in a small pilot model. The purpose of this project is to build a full-scale prototype model to reach a final design that can form the basis for a manufacturing line for Acapsil. Without this, it will not be possible to produce Acapsil to cover the medical need. This will mean lost opportunity to help patients with debilitating wounds and loss of important export and job opportunites to the UK.

Acapsil是一种获得CE认证的新型一流先进生物材料，已在伤口护理中显示出效果。在英国，每年有220万伤口需要治疗，导致NHS的直接成本为53亿英镑。Acapsil可使急性和慢性伤口和溃疡住院患者的伤口愈合速度加快60%，住院天数减少31%。据估计，Acapsil可以将伤口护理成本降低25- 30%。Acapsil在全球所有主要市场都获得了专利。Acapsil的性能在很大程度上取决于生产工艺，目前该工艺中的一个步骤阻碍了大规模生产。大量的研究致力于解决这个问题，已经找到了一个解决方案，该解决方案已经过测试，并证明在小型试验模型中有效。该项目的目的是建立一个全尺寸的原型模型，以达到最终的设计，可以形成Acapsil生产线的基础。没有这一点，就不可能生产Acapsil来满足医疗需求。这将意味着失去帮助受伤患者的机会，失去对英国的重要出口和就业机会。